The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โABBVโ.
According to AbbVie's latest financial reports the company's total liabilities are $121.51 B. A companyโs total liabilities is the sum of all current and non-current debts and obligations.
Year | Total liabilities | Change |
---|---|---|
2022-12-31 | $121.51 B | -7.3% |
2021-12-31 | $131.09 B | -4.64% |
2020-12-31 | $137.46 B | 41.3% |
2019-12-31 | $97.28 B | 43.5% |
2018-12-31 | $67.79 B | 3.21% |
2017-12-31 | $65.68 B | 6.88% |
2016-12-31 | $61.46 B | 25.17% |
2015-12-31 | $49.10 B | 90.29% |
2014-12-31 | $25.80 B | 4.45% |
2013-12-31 | $24.70 B | 4.49% |
2012-12-31 | $23.64 B | 218.09% |
2011-12-31 | $7.43 B | 36.85% |
2010-12-31 | $5.43 B |
Company | Total liabilities | differencediff. | Country |
---|---|---|---|
![]() Pfizer PFE | $101.28 B | -16.65% | ๐บ๐ธ USA |
![]() Eli Lilly LLY | $41.86 B | -65.55% | ๐บ๐ธ USA |
![]() Amgen AMGN | $83.37 B | -31.39% | ๐บ๐ธ USA |
![]() Biogen BIIB | $10.81 B | -91.10% | ๐บ๐ธ USA |
![]() Gilead Sciences GILD | $40.93 B | -66.31% | ๐บ๐ธ USA |
![]() Bristol-Myers Squibb BMY | $62.39 B | -48.65% | ๐บ๐ธ USA |
![]() AstraZeneca AZN | $60.87 B | -49.90% | ๐ฌ๐ง UK |
![]() GlaxoSmithKline GSK | $58.57 B | -51.80% | ๐ฌ๐ง UK |
![]() Neurocrine Biosciences
NBIX | $0.67 B | -99.44% | ๐บ๐ธ USA |